3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Diabetes Mellitus, Insulin-Dependent, 12
6
Carcinoma, Non-Small-Cell Lung
6
Carcinoma, Hepatocellular
6
Melanoma
5
Breast Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Small Cell Lung Carcinoma
3
Recurrence
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Urinary Bladder Neoplasms
2
Recurrent Squamous Cell Lung Carcinoma
2
Ovarian Neoplasms
2
Mesothelioma
2
Lung Neoplasms
2
Liver Neoplasms
2
Fallopian Tube Neoplasms
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Vascular Neoplasms
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Testicular Neoplasms
1
Solid Tumor
1
Sarcoma, Synovial
1
Interventions
Rituximab
134
Cyclophosphamide
100
Vincristine
53
fludarabine phosphate
50
Prednisone
50
Doxorubicin
49
Etoposide
47
Peripheral Blood Stem Cell Transplantation
38
Mycophenolic Acid
37
Whole-Body Irradiation
35
Tacrolimus
29
Busulfan
27
Lenalidomide
26
Filgrastim
26
Cyclosporine
26
Melphalan
24
Methotrexate
21
Antilymphocyte Serum
21
Gemcitabine
18
ibritumomab tiuxetan
17
Granulocyte Colony-Stimulating Factor
17
Cytarabine
17
Carmustine
16
Radiotherapy
15
fludarabine
14
Carboplatin
14
Bendamustine Hydrochloride
14
pembrolizumab
13
ibrutinib
12
Sirolimus
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, Large B-Cell, Diffuse
×
tremelimumab
×
Clear all
NCT02205333
2017-06-28
MEDI6469
MedImmune LLC
Phase 1/2
Terminated
48 enrolled
28 charts